Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
APPA, is a patented, combination oral therapy of two synthetically produced isomers, an investigational NFkB and Nrf2 modulator, essential for maintaining coordinated cellular responses to resolve the inflammatory status of the cell/tissue.
Lead Product(s): APPA
Therapeutic Area: Musculoskeletal Product Name: APPA
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Results from the study, conducted by Instituto de Investigación Biomedica da Coruña, Spain, found that APPA, an NRf2 and NFkB regulator, has a clear anti-inflammatory effect on human articular chondrocytes, and could reduce extracellular matrix degradation of cartilage.
Lead Product(s): CAS 498-02-2,Paeonol
Therapeutic Area: Musculoskeletal Product Name: APPA
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
Results from one study, conducted by Nordic Biosciences found that APPA, an NRf2 and NFkB regulator, reduces inflammation-derived tissue turnover in human cartilage explants and inhibits RANKL-mediated osteoclastogenesis and bone resorption by human osteoclasts.
Lead Product(s): AKL4
Therapeutic Area: Musculoskeletal Product Name: APPA
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021